To explore the effect of LTA on clinical symptoms in letrozole-induced PCOS rats. Female SD rats were given letrozole for 28 consecutive days to induce the PCOS model. The PCOS rats were given LTA intervention(50 and 200 mg/kg) for 30 days. Changes in...
To explore the effect of LTA on clinical symptoms in letrozole-induced PCOS rats. Female SD rats were given letrozole for 28 consecutive days to induce the PCOS model. The PCOS rats were given LTA intervention(50 and 200 mg/kg) for 30 days. Changes in body weight and estrous cycle were observed. Serum levels of hormones and lipids were measured by ELISA assay. Protein levels of α-SMA, p-smad2, smad2, p-smad3, smad3 and smad4 were detected by Western Blotting assay. Compared with the normal group, the relative mass of abdominal fat, T, LH, INS, TG, TC and LDL-C were significantly increased, and the levels of E2, FSH and HDL-C were significantly decreased in PCOS rats. The protein levels of p-smad2, p-smad3, smad4 and α-SMA were significantly upregulated in the ovaries of PCOS rats(P<0.05). While the levels of T, LH, INS, TG, TC, LDL-C were decreased and E2, FSH and HDL-C level were increased by LTA treatment. Meanwhile, LTA reduced the protein levels of p-smad2, p-smad3, smad4, and α-SMA in the ovaries. The results suggested LTA was effective in regulating the hormone levels, improving metabolism, and alleviating ovarian fibrosis in PCOS rats.